Full-Year Profit Generation in the Testing Business
First written in FY2018-Q1. 12 of 28 entries say "Worsened", first in FY2020-Q1. Latest entry: 2026-05-28.
Immuno-Biological Laboratories moved to the "Worse" side of this theme in 2025.
0 other companies' latest entry also says "Worsened".
- 2026-05-28WorsenedPresentation materials on financial results
「Testing services 31,841 — 3.2% (△50.3%)」
Full-year revenue from testing services was ¥31.841 million, down 50.3% year on year. The business foundation for the full-year profit-generation target deteriorated. - FY2026-H1WorsenedAnnual report
「Revenue from the service declined 49.1% year on year to ¥16.158 million because there were no sizable domestic or overseas tests related to the blood lipoprotein profiling service LipoSEARCH® and the number of clinical laboratory service tests decreased.」
Inspection services generated revenue of ¥16.158 million, down 49.1% year on year, as there were no sizeable LipoSEARCH-related testing orders and the number of clinical tests also declined. The business foundation for the first half deteriorated relative to the full-year profit-generation target, while no full-year earnings figure was disclosed. - FY2025-H1AdvancedAnnual report
「Revenue for the business during the first six months of the current consolidated fiscal period increased 41.3% year on year to ¥2.977 million, mainly because sales through domestic mail order increased sales to distributors. Operating income was ¥0.723 million, compared with an operating loss of ¥3.079 million in the same period of the previous year.」
The cosmetics-related business recorded operating income of ¥0.723 million in the first half, turning profitable from the ¥3.079 million operating loss recorded in the same period of the previous year. Although this did not represent achievement of the full-year profit-generation target, it was tangible improvement at the first-half stage. - FY2024WorsenedAnnual report
「Inspection services generated revenue of ¥61.163 million and recorded an operating loss of ¥2.046 million.」
The inspection business recorded a full-year operating loss of ¥2.046 million, missing its full-year profit-generation target. Revenue also declined 4.8% year on year. - FY2024-Q3WorsenedAnnual report
「Inspection services ¥48.401 million -¥1.737 million -3.5% -¥7.203 million -¥3.947 million -」
Inspection services generated revenue of ¥48.401 million, down 3.5% year on year, while the operating loss widened by ¥3.947 million from the same period of the previous year to ¥7.203 million. Against the full-year profit-generation target, the business remained in the red for the cumulative third quarter period. - FY2024-Q2AdvancedAnnual report
「Inspection services ¥29.660 million -¥0.709 million -2.3% -¥3.515 million +¥2.745 million -」
Inspection services generated revenue of ¥29.660 million, down 2.3% year on year, and recorded an operating loss of ¥3.515 million. Revenue declined only slightly, and the operating loss narrowed by ¥2.745 million from the same period of the previous year, but the business had not yet turned profitable. - FY2024-Q1WorsenedAnnual report
「Inspection services ¥11.375 million -¥0.898 million -7.3% -¥5.117 million -¥0.285 million -」
Inspection services generated revenue of ¥11.375 million, down 7.3% year on year, and recorded an operating loss of ¥5.117 million. Against the objective of generating a full-year profit, the first quarter saw lower revenue and a larger loss than the same period of the previous year. - FY2023AdvancedAnnual report
「In the testing services business, tests related to the blood lipoprotein profiling service LipoSEARCH stagnated and declined year on year amid the COVID-19 pandemic. Meanwhile, revenue from contract measurement services using the Company's ELISA kits at clinical laboratories increased.」
Inspection services recorded an operating loss of ¥3.497 million due to a decline in LipoSEARCH-related testing, but the loss narrowed from the ¥17.038 million operating loss recorded in the same period of the previous year, as contract testing using the company’s own ELISA kits increased. - FY2023-Q3AdvancedAnnual report
「In the testing services business, tests related to the blood lipoprotein profiling service LipoSEARCH stagnated and declined year on year amid the COVID-19 pandemic. Meanwhile, revenue from contract measurement services using the Company's ELISA kits at clinical laboratories increased.」
Inspection services recorded an operating loss of ¥3.255 million due to a decline in LipoSEARCH-related testing, but the loss narrowed by ¥13.782 million from the same period of the previous year. The business had not yet begun generating a full-year profit. - FY2023-Q2AdvancedAnnual report
「Inspection services ¥30.370 million +¥2.900 million +10.6% -¥6.260 million +¥18.879 million -」
Inspection services generated revenue of ¥30.370 million, up 10.6% year on year, while the operating loss improved by ¥18.879 million from the same period of the previous year to ¥6.260 million. The business had not yet turned profitable for the cumulative second quarter period. - FY2023-Q1WorsenedAnnual report
「Testing services ¥12.274 million ¥5.461 million loss -30.8% ¥4.832 million loss ¥317,000 loss —」
Inspection services generated revenue of ¥12.274 million, down 30.8% year on year, and recorded an operating loss of ¥4.832 million. Against the objective of generating a full-year profit, the first quarter saw lower revenue and a larger loss than the same period of the previous year. - FY2022-Q3AdvancedAnnual report
「Results for the nine months ended the third quarter increased from the previous fiscal year after the company received an order for a large LipoSEARCH project from an existing pharmaceutical company customer. With sales activities such as exhibiting at academic conferences in Japan and overseas and face-to-face visits continuing to be restricted, the company will work to disseminate information using the web.」
The testing services business increased year on year due to an order for a large LipoSEARCH project. The segment operating loss also narrowed to ¥17.038 million from the previous year, but the business has not yet reached full-year profitability. - FY2022-Q1AdvancedAnnual report
「As a result, segment revenue was ¥17.836 million, up 52.9% year on year, and the operating loss was ¥4.514 million, compared with an operating loss of ¥9.443 million in the same period of the previous year.」
The testing business's revenue increased 52.9% year on year, while the operating loss narrowed from ¥9.443 million to ¥4.514 million. Improvement toward the full-year profit-generation target is evident, but the business remained loss-making in the current quarter. - FY2021MitigatedAnnual report
「As a result, segment revenue was ¥81.462 million, up 13.7% year on year, and the operating loss was ¥17.043 million, compared with an operating loss of ¥26.227 million in the same period of the previous year.」
The testing business remained loss-making on a full-year basis, but revenue increased 13.7% year on year and the operating loss narrowed from ¥26.227 million to ¥17.043 million. - FY2021-Q2WorsenedAnnual report
「As a result, segment revenue was ¥26.394 million, down 31.7% year on year, and the operating loss was ¥17.917 million, compared with an operating loss of ¥12.534 million in the same period of the previous year.」
The testing business's revenue declined 31.7% year on year, and the operating loss widened from ¥12.534 million to ¥17.917 million. The business remained in the red for the first half relative to the full-year profit-generation target. - FY2021-Q1WorsenedAnnual report
「As a result, segment revenue was ¥11.665 million, down 35.1% year on year, and the operating loss was ¥9.443 million, compared with an operating loss of ¥5.804 million in the same period of the previous year.」
The testing business's revenue declined 35.1% year on year, while the operating loss widened from ¥5.804 million to ¥9.443 million. Stagnation among LipoSEARCH-related business partners and difficulty securing large projects were factors. - FY2020WorsenedAnnual report
「As a result, segment revenue was ¥71.636 million, compared with ¥152.000 million in the medium-term plan and down 43.8% year on year, while the operating loss was ¥26.227 million, compared with the ¥25.000 million profit projected in the medium-term plan and operating profit of ¥12.847 million in the same period of the previous year.」
The testing business swung from full-year profitability in the previous fiscal year to an operating loss of ¥26.227 million in the current fiscal year, falling short of the planned profit of ¥25.000 million. - FY2020-Q3WorsenedAnnual report
「As a result, segment revenue was ¥57.621 million, down 40.6% year on year, and the operating loss was ¥20.343 million, compared with operating profit of ¥11.393 million in the same period of the previous year.」
The testing business's revenue declined 40.6% year on year because there was no large LipoSEARCH project, and it swung from operating profit of ¥11.393 million in the same period of the previous year to an operating loss of ¥20.343 million. Sales efforts targeting major customers, expansion of contracted ELISA testing, private-pay medical services and overseas licensing-out initiatives are continuing. - FY2020-Q2WorsenedAnnual report
「As a result, segment revenue was ¥38.645 million, down 46.0% year on year, and the operating loss was ¥12.534 million, compared with operating profit of ¥12.081 million in the same period of the previous year.」
The testing business swung from operating profit of ¥12.081 million in the same period of the previous year to an operating loss of ¥12.534 million, and earnings for the six months ended the second quarter deteriorated relative to the full-year profit-generation target. - FY2020-Q1WorsenedAnnual report
「As a result, segment revenue was ¥17.960 million, down 42.7% year on year, and the operating loss was ¥5.804 million, compared with an operating loss of ¥1.140 million in the same period of the previous year.」
The testing business's operating loss widened from ¥1.140 million in the same period of the previous year to ¥5.804 million. Quarterly earnings have deteriorated relative to the full-year profit-generation target. - FY2019AchievedAnnual report
「As a result, segment revenue was ¥127.392 million, up 9.8% year on year, and operating profit was ¥12.847 million, up 20.8% year on year.」
The testing business recorded full-year operating profit of ¥12.847 million and achieved its full-year profit-generation target. Large orders for LipoSEARCH and ELISA testing contributed. - FY2019-Q3AdvancedAnnual report
「In this business, we were able to recognize sales from a large LipoSEARCH project, the main service of the blood lipoprotein profiling business. Going forward, we will continue to share sales activities with the diagnostics and reagents division, actively conduct promotional activities at academic conferences, and strengthen promotional activities in both markets. As a result, segment revenue was ¥96.944 million, up 13.8% year on year, and operating profit was ¥11.393 million, up 67.6% year on year. The business will continue to aim to generate a full-year profit, as it did in the previous fiscal year.」
The testing business recognized sales from a large LipoSEARCH project, generating revenue of ¥96.944 million and operating profit of ¥11.393 million. Operating profit increased 67.6% year on year, and the full-year profit-generation target remains unchanged. - FY2019-Q2AdvancedAnnual report
「As a result, segment revenue was ¥71.591 million, up 23.4% year on year, and operating profit was ¥12.081 million, up 147.6% year on year. The business will continue to aim to generate a full-year profit, as it did in the previous fiscal year.」
The testing business generated revenue of ¥71.591 million and operating profit of ¥12.081 million, recording year-on-year increases in both revenue and profit. The full-year profit-generation target remains unchanged. - FY2019-Q1RestatedAnnual report
「In this business, we aim to generate a profit for the full year.」
The company continues to target full-year profitability in the testing business. Although it recorded an operating loss of ¥1.140 million in the first quarter, no withdrawal or change to the full-year target has been disclosed. - FY2018AchievedAnnual report
「For the current fiscal year, revenue increased 10.2% year on year to ¥115.988 million. The previous fiscal year's comparative period recorded an operating loss of ¥18.309 million, whereas the current consolidated fiscal year recorded operating profit of ¥10.634 million, indicating that both the diagnostics and reagents divisions are beginning to deliver results.」
The testing business recorded full-year operating profit of ¥10.634 million, returning to profitability from an operating loss in the previous year. Although the full-year profit-generation target was achieved in the current fiscal year, stable profitability remains an ongoing target. - FY2018-Q3AdvancedAnnual report
「In this business, we actively conducted promotional activities at academic conferences in Japan and overseas, and orders for large projects and other contracts increased, resulting in higher revenue year on year. As a result, segment revenue was ¥85.187 million, up 4.9% year on year, and operating profit was ¥6.796 million, compared with an operating loss of ¥12.790 million in the same period of the previous year. The business will continue to aim for stable profitability.」
The testing business recorded operating profit of ¥6.796 million, returning to profitability from an operating loss in the same period of the previous year. The goal of stable full-year profitability remains unchanged. - FY2018-Q2AdvancedAnnual report
「As a result, segment revenue was ¥58.030 million, up 33.5% year on year, and operating profit was ¥4.879 million, compared with an operating loss of ¥18.152 million in the same period of the previous year. The business became profitable on a cumulative basis through the second quarter of the current fiscal year, and aims to maintain stable profitability for the full year.」
The testing business recorded operating profit of ¥4.879 million for the six months ended the second quarter, returning to profitability from an operating loss in the same period of the previous year. The goal of stable full-year profitability remains unchanged. - FY2018-Q1First statedAnnual report
「In this business, we aim to generate a profit for the full year.」
Against a backdrop of promotional activities at academic conferences in Japan and overseas and increased sales, the company has stated for the first time that it aims to generate a full-year profit in the testing business.